Session Information
Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Systemic autoimmune diseases (SADs) are chronic inflammatory conditions with autoimmune aetiology and many common clinical features, difficulting diagnosis and adequate treatment decisions. Finding new treatments or applying the existing ones in a more effective way is especially hard in SADs due to the heterogeneity of molecular mechanisms within the same disease class. Based on this premise, the first step towards establishing a precision medicine strategy for SADs is to reclassify these conditions at the molecular level, which might result in a more homogenous stratification in terms of pathological molecular pathways. SADs have a multi-factorial predisposition, where the interplay between genetic, epigenetic and environmental conditions is essential in the pathogenesis of the diseases. Thus, in order to capture as many aspects as possible the molecular stratification is performed using multiple layers of information (e.g. genome, transcriptome, methylome or metabolome). Among all available molecular levels of information, the most informative in terms of functionality and dimensionality are transcriptome and methylome, reflecting different aspects of regulation and environmental influence, respectively, giving a wide view of the molecular background.
Methods: We performed an unsupervised integrative clustering analysis to classify SADs patients into subtypes based on genome-wide trancriptome and methylome profiling of ~800 cases distributed across 7 different clinical entities (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, primary Sjögren ́s syndrome, primary antiphospholipid antibody syndrome, mixed connective tissue disease and undifferentiated connective tissue disease) and ~200 healthy individuals.
Results: Interestingly, patients with different diagnoses were grouped statistically into new groups in terms of molecular functions. These results were replicated in two independent subsets of patients. The new groups of patients are characterized by a major subdivision, where some clusters show an increased inflammatory response and neutrophil degranulation functions, while others are enriched in lymphocyte proliferation and differentiation signatures. This major signal is subdivided into more specific subgroups defined by functional signatures such as type I interferon signaling, complement activation or neural functionalities among others.
Conclusion: This is the first attempt of integrating and characterizing SADS patients based on molecular profiles. The results show that we are able to identify new groups of patients sharing molecular features that do not reflect the clinical diagnoses. This new molecular classification might suppose a first step through precision medicine in SADS.
To cite this abstract in AMA style:
Barturen G, Babaei S, Catala-Moll F, Makowska Z, García-Gómez A, Buttgereit A, Carnero-Montoro E, Hayat S, Kerick M, Charlon T, Gemperline DC, Le Lann L, Quirantes-PIné R, Borrás-Linares I, Muchmore B, Kageyama J, Rodríguez-Ubreva J, Fernández-Ochoa A, Carmona Sanz P, Jamin C, Lesche R, Benschop RJ, Chamberlain C, Dow ER, Gomes T, Juárez M, Laigle L, Marovac J, MacDonald F, Wojcik J, Ballestar E, Beretta L, Borghi MO, Frostegård J, Garcia ML, Martín J, Pers JO, Renadineau Y, Segura Carretero A, Alarcón-Riquelme M. Transcriptome and Methylome Integrative Molecular Analysis Uncovers a New Systemic Autoimmune Disease Classification [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/transcriptome-and-methylome-integrative-molecular-analysis-uncovers-a-new-systemic-autoimmune-disease-classification/. Accessed .« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/transcriptome-and-methylome-integrative-molecular-analysis-uncovers-a-new-systemic-autoimmune-disease-classification/